60 Degrees Pharmaceuticals, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.54
- 52-Week Range
- $0.46 – $8.62
- Market Cap
- $2.24M
- P/E (TTM)
- —
- EPS (TTM)
- -5.34
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- -327.36%
- Return on Assets
- -112.56%
- Gross Margin
- -50.27%
- Operating Margin
- -957.98%
- Profit Margin
- 0.00%
- Current Ratio
- 1.17
- Debt/Equity
- 0.20
- Total Debt
- $150.40K
- Free Cash Flow
- $-5.66M
- Revenue Growth
- -55.90%
- Earnings Growth
- —
- Enterprise Value
- $10.69M
Market Snapshot
About
60 Degrees Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for the treatment and prevention of infectious diseases. The company is advancing tafenoquine, an 8-aminoquinoline antimalarial drug, for malaria prevention in travelers and military personnel. It leverages partnerships to develop and commercialize its product candidates.